The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone
The company announced positive topline data from the Phase 3 ADorable-1 trial
One task, one interaction, one pair, experts advocate
The conflict is also triggering a widening public health emergency
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
